Welcome to CDC stacks | Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis - 54628 | Morbidity and Mortality Weekly Report (MMWR)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis
Filetype[PDF-117.55 KB]


Details:
  • Personal Authors:
    Nelson, Noele P.
  • Keywords:
  • Pubmed ID:
    28910270
  • Pubmed Central ID:
    PMC5657912
  • Description:
    GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella viruses (1). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma (2). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.

  • Document Type:
    Journal Article
  • Collection(s):
    Morbidity and Mortality Weekly Report (MMWR)
  • Main Document Checksum:
No Related Documents.
You May Also Like:
  1. Considerations for use of hepatitis A vaccines for post-exposure prophylaxis and international travel
    Personal Author:
    Nelson, Noele
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). United States. Advisory Committee on Immunization Practices. Hepatitis Vaccines Work Group..
    Conference Author:
    United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
    Published:
    4/9/18
    Series:
    ACIP meeting Hepatitis Vaccines
    Description:
    Presentations February 2018 Day 1 : Publication date from document properties. : Hepatitis-04a-Nelson-508.pdf
    File Type:
    Filetype[PDF - 714.17 KB]
  2. MMWR. Morbidity and mortality weekly report, Vol. 66, no. 36, September 15, 2017
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    September 15, 2017
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 66, no. 36
    Description:
    National Preparedness Month — September 2017 -- Assessment of Hospital Emergency Department Response to Potentially Infectious Diseases Using Unannounced Mystery Patient Drills — New York City, 2016 -- Rates and Trends of Pediatric Acute Lymphobl...
    File Type:
    Filetype[PDF - 611.82 KB]
  3. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
    Personal Author:
    Nelson, Noele P.; Link-Gelles, Ruth; Hofmeister, Megan G.; Romero, José R.; Moore, Kelly L.; Ward, John W.; Schillie, Sarah F.;
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    Nov 02 2018
    Source:
    MMWR Morb Mortal Wkly Rep. 67(43):1216-1220
    Description:
    Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the...
    File Type:
    Filetype[PDF - 109.44 KB]
  4. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
    Personal Author:
    Nelson NP, Link-Gelles R, Hofmeister MG, et al.
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    November 2, 2018
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 43
    Description:
    Postexposure prophylaxis (PEP) with hepatitis A (HepA)
    Status:
    current
    File Type:
    Filetype[PDF - 114.31 KB]
  5. Supplementary text 1. Provider Guidance on Risk Assessment and Clinical Decision-making for Hepatitis A Postexposure Prophylaxis. Supplements: Update: Recommendations of the Advisory Committee on Immunization Practices for use of Hepatitis A vaccine for post-exposure prophylaxis and for international travel
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    November 2, 2018
    Source:
    Update: Recommendations of the Advisory Committee on Immunization Practices for use of Hepatitis A vaccine for post-exposure prophylaxis and for international travel. MMWR. Morbidity and mortality weekly report ; v. 67, no. 43, p.
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 43, p.
    File Type:
    Filetype[PDF - 193.35 KB]